https://www.selleckchem.com/products/lxs-196.html
374) and RLS (SMD=1.086), while most PSG parameters remained unchanged, except for shortened rapid eye movement sleep latency (RSL) (SMD=0.52. In the over-12-month follow-up, improvement persisted in PDSS but not in ESS. Dopamine drug reduction (p=0.009) and motor improvement (p=0.036) were correlated with ESS improvement and PDSS improvement, respectively. Bilateral STN-DBS continuously improved subjective nocturnal sleep, while its effect on ESS lasted for only 1 year. Medication reduction and motor improvement may contribute to imp
Like
Comment
Share
